01/24/2023

Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

01/19/2023

Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

01/18/2023

Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock

01/03/2023

Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company

01/03/2023

Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only

01/03/2023

Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference

12/01/2022

Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit

11/08/2022

Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences

11/03/2022

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results

10/27/2022

Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022